Publication Category: Medications
Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration
-
Galofré JC, Díez JJ, Attanasio R, Nagy EV, Negro R, Papini E, Perros P, Žarković M, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Dobnig H, Fadeyev V, Field BCT, Fliers E, Führe
Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration J Endocrinol Invest
Determinants of adherence to obesity medication: A narrative review
-
Sharma AM, Birney S, Crotty M, Finer N, Segal-Lieberman G, Vázquez-Velázquez V, Vrijens B.
Determinants of adherence to obesity medication: A narrative review Obes Rev
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m(2) in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
-
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hussain SA, Hennige AM.
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m(2) in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist Diabetes Obes Metab
A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure
-
Gul U, Aung T, Martin M, Farrukh DN, Shah PC, Lovely ZS, Marroquín León E, Alansaari M, Maini S, Fariduddin MM, Ullah A, Nazir Z.
A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure Cureus
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)
-
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE‐1 and ‐2 trial committees and investigators.
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring)
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
-
Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, Unseld A, Startseva E, Kaplan LM; SYNCHRONIZE–CVOT Trial Committees and Investigators.
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial JACC Heart Fail
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
- Kueh MTW, Chong MC, Miras AD, le Roux CW. Oxyntomodulin physiology and its therapeutic development in obesity and associated complications J Physiol
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)
-
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE‐1 and ‐2 trial committees and investigators.
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring)